In one paragraphArticle in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Jaques van Heerden *Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Stellenbosch University, Tygerberg Campus, Francie van Zijl Drive, Cape Town, Western Cape, 7505, South Africa, 27 219389506.ORCID http://orcid.org/0000-0002-4502-1169 Mariana Kruger *Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Stellenbosch University, Tygerberg Campus, Francie van Zijl Drive, Cape Town, Western Cape, 7505, South Africa, 27 219389506.ORCID http://orcid.org/0000-0002-6838-0180 Anel van Zyl *Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Stellenbosch University, Tygerberg Campus, Francie van Zijl Drive, Cape Town, Western Cape, 7505, South Africa, 27 219389506.ORCID http://orcid.org/0000-0003-3370-0874 James Warwick *Department of Nuclear Medicine, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0002-2810-0543 Celeste Burger *Department of Nuclear Medicine, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0002-7288-6790 Tumelo Moalosi *Department of Nuclear Medicine, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0002-6289-9512 Christoffel van Reenen *Department of Nuclear Medicine, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0002-6720-1101 Alan Davidson *Division of Paediatric Haematology and Oncology, Red Cross War Memorial Children's Hospital, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0002-4646-4332 Khanyisile Hlongwa *Division of Nuclear Medicine, Red Cross War Memorial Children's Hospital, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0003-0634-6339 Daniella Violante *Division of Nuclear Medicine, Red Cross War Memorial Children's Hospital, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0009-0009-5267-1256 Nanette Bruwer *Department of Nuclear Medicine, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0009-0007-2001-1304 Gita Naidu *Department of Paediatric Haemato-Oncology, Department of Paediatrics and Child Health, University of the Witwatersrand, Chris Hani Baragwanath Academic Hospital, Johannesburg, Gauteng, South Africa.ORCID http://orcid.org/0000-0002-4412-3825 Biance Rowe *Department of Paediatric Haemato-Oncology, Department of Paediatrics and Child Health, University of the Witwatersrand, Chris Hani Baragwanath Academic Hospital, Johannesburg, Gauteng, South Africa.ORCID http://orcid.org/0000-0001-8161-0596 Anita Brink *Nuclear Medicine and Diagnostic Imaging Section, Division of Human of Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.ORCID http://orcid.org/0000-0001-8658-2379 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Background: In South Africa, the metastatic response rate for stage 4 high-risk neuroblastoma (HR-NB) to induction chemotherapy is lower than that of similar regimens in well-resourced settings. Augmenting current induction chemotherapy regimens with molecular radiotherapy, without increasing toxicity, is an attractive systemic treatment in radioisotope-avid tumors, especially in a resource-limited setting where stem cell transplantation and immunotherapy are unavailable and costly. Clinical trials of [ Objective: The aim of the proof-of-concept, open-label study is to evaluate the safety and efficacy of induction [ Methods: The LuDO-SA trial is a phase 1, open-label, multicenter, 2-arm, randomized controlled clinical trial. Children aged 18 months to 18 years are eligible. The experimental arm, consisting of a single dose of [ Results: The trial received institutional ethics approval from 4 South African universities in 2022 and SAHPRA (South African Health Products Regulatory Authority) regulatory approval. The trial, funded by Kinderkankerfonds vzw and the UZA Foundation, commenced recruitment in January 2023. As of July 2026, a total of 15 patients have been enrolled across 4 academic hospital sites. Recruitment is projected to be completed by June 2027, with results expected to be published in December 2027. Conclusions: In this paper, we present the protocol of the LuDO-SA trial. The rationale and design of the trial in a resource-limited setting and its use in first-line regimens are discussed, and the current status of international [
Indexed as
Induction ChemotherapyNeuroblastomaOctreotideOrganometallic CompoundsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolClinical Trials, Phase I as TopicEtoposideFemaleHumansInfantMaleRandomized Controlled Trials as TopicSouth AfricaEtoposidelutetium Lu 177 dotatateOctreotideOrganometallic Compounds[first-line therapyhigh-riskmetastatic remissionneuroblastomapeptide receptor radionuclide therapyPRRTradiopharmaceuticalSouth Africa
Identifiers
PMID42814905
PMCPMC13626406
What Socratic holds
Textmetadata
Read underepoch 390